Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG0001 in Critical Limb Ischemia
NCT02144610Phase 3Terminated
- Sponsor
- AnGes, Inc.
- Start
- Nov 2014
- Primary completion
- Nov 2016
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 11
01
Overview
A Phase 3 trial of beperminogene perplasmid in critical limb ischemia (CLI), sponsored by AnGes, Inc.. Started Nov 2014; status: terminated.
02
Drugs
beperminogene perplasmid
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02144610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144610.